{"_links": {"parentPackage": {"href": "/mdr/ct/packages/protocolct-2023-03-31", "title": "Protocol Controlled Terminology Package 53 Effective 2023-03-31", "type": "Terminology"}, "priorVersion": {"href": "/mdr/ct/packages/protocolct-2022-12-16/codelists/C170441", "title": "CDISC Protocol Endpoint Type Value Set Terminology", "type": "Code List"}, "rootItem": {"href": "/mdr/root/ct/protocolct/codelists/C170441", "title": "Version-agnostic anchor resource for codelist C170441", "type": "Root Value Domain"}, "self": {"href": "/mdr/ct/packages/protocolct-2023-03-31/codelists/C170441", "title": "CDISC Protocol Endpoint Type Value Set Terminology", "type": "Code List"}}, "conceptId": "C170441", "definition": "The terminology relevant to the type of endpoint for the study.", "name": "Endpoint Type Value Set Terminology", "preferredTerm": "CDISC Protocol Endpoint Type Value Set Terminology", "submissionValue": "Endpoint Type Value Set Terminology", "synonyms": ["Endpoint Type Value Set Terminology"], "terms": [{"conceptId": "C170561", "definition": "Endpoint(s) constructed from two or more endpoints that represents an overall clinically relevant measure of clinical benefit.", "preferredTerm": "Composite Endpoint", "submissionValue": "Composite Endpoint", "synonyms": ["Combined Endpoint"]}, {"conceptId": "C170560", "definition": "Endpoint(s) used in clinical studies to directly measure how a patient feels, functions, or survives. These endpoint(s) in themselves represent or characterize the clinical outcome of interest. (FDA: https://www.fda.gov/media/84987/download)", "preferredTerm": "Direct Endpoint", "submissionValue": "Direct Endpoint"}, {"conceptId": "C170559", "definition": "Endpoint(s) that may include clinically important events that are expected to occur too infrequently to show a treatment effect or endpoints that for other reasons are thought to be less likely to show an effect but are included to explore new hypotheses. (After FDA-NIH Protocol Template)", "preferredTerm": "Exploratory Endpoint", "submissionValue": "Exploratory Endpoint"}, {"conceptId": "C94496", "definition": "Endpoint(s) of greatest importance that is the basis for concluding whether the study met its objective(s) and provides a clinically relevant, valid, and reliable measure of the primary objective(s). (After FDA-NIH Protocol Template)", "preferredTerm": "Primary Endpoint", "submissionValue": "Primary Endpoint"}, {"conceptId": "C139173", "definition": "Endpoint(s) that may provide supportive information about the effect of the study intervention(s) on the primary endpoint or demonstrate additional effects on the disease or condition. (After FDA-NIH Protocol Template)", "preferredTerm": "Secondary Endpoint", "submissionValue": "Secondary Endpoint"}, {"conceptId": "C68772", "definition": "An endpoint that is used in clinical trials as a substitute for a direct measure of how a patient feels, functions, or survives. A surrogate endpoint does not measure the clinical benefit of primary interest in and of itself, but rather is expected to predict that clinical benefit or harm based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. (NIH-FDA BEST (Biomarkers, Endpoints, and other Tools) Resource)", "preferredTerm": "Surrogate Endpoint", "submissionValue": "Surrogate Endpoint"}]}